Attributable risk estimate of severe psoriasis on major cardiovascular events
- PMID: 21787906
- PMCID: PMC3146037
- DOI: 10.1016/j.amjmed.2011.03.028
Attributable risk estimate of severe psoriasis on major cardiovascular events
Abstract
Background: Recent studies suggest that psoriasis, particularly if severe, may be a risk factor for major adverse cardiac events, such as myocardial infarction, stroke, and mortality from cardiovascular disease. We compared the risk of major adverse cardiac events between patients with psoriasis and the general population and estimated the attributable risk of severe psoriasis.
Methods: We performed a cohort study in the General Practice Research Database. Severe psoriasis was defined as receiving a psoriasis diagnosis and systemic therapy (N=3603). Up to 4 patients without psoriasis were selected from the same practices and start dates for each patient with psoriasis (N=14,330).
Results: Severe psoriasis was a risk factor for major adverse cardiac events (hazard ratio 1.53; 95% confidence interval, 1.26-1.85) after adjusting for age, gender, diabetes, hypertension, tobacco use, and hyperlipidemia. After fully adjusted analysis, severe psoriasis conferred an additional 6.2% absolute risk of 10-year major adverse cardiac events.
Conclusion: Severe psoriasis confers an additional 6.2% absolute risk of a 10-year rate of major adverse cardiac events compared with the general population. This potentially has important therapeutic implications for cardiovascular risk stratification and prevention in patients with severe psoriasis. Future prospective studies are needed to validate these findings.
Copyright © 2011 Elsevier Inc. All rights reserved.
Conflict of interest statement
Similar articles
-
Prevalence of cardiovascular risk factors in patients with psoriasis.J Am Acad Dermatol. 2006 Nov;55(5):829-35. doi: 10.1016/j.jaad.2006.08.040. Epub 2006 Sep 25. J Am Acad Dermatol. 2006. PMID: 17052489
-
Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database.Eur Heart J. 2010 Apr;31(8):1000-6. doi: 10.1093/eurheartj/ehp567. Epub 2009 Dec 27. Eur Heart J. 2010. PMID: 20037179 Free PMC article.
-
Psoriasis and the Risk of Major Cardiovascular Events: Cohort Study Using the Clinical Practice Research Datalink.J Invest Dermatol. 2015 Sep;135(9):2189-2197. doi: 10.1038/jid.2015.87. Epub 2015 Mar 5. J Invest Dermatol. 2015. PMID: 25742120
-
Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment.Int J Mol Sci. 2017 Oct 21;18(10):2211. doi: 10.3390/ijms18102211. Int J Mol Sci. 2017. PMID: 29065479 Free PMC article. Review.
-
Psoriasis: the visible killer.Rev Port Cardiol. 2014 Feb;33(2):95-9. doi: 10.1016/j.repc.2013.06.017. Epub 2014 Feb 10. Rev Port Cardiol. 2014. PMID: 24525359 Review.
Cited by
-
Hyperlipidaemia and IFNgamma/TNFalpha Synergism are associated with cholesterol crystal formation in Endothelial cells partly through modulation of Lysosomal pH and Cholesterol homeostasis.EBioMedicine. 2020 Sep;59:102876. doi: 10.1016/j.ebiom.2020.102876. Epub 2020 Jul 6. EBioMedicine. 2020. PMID: 32646751 Free PMC article.
-
Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis.Br J Dermatol. 2022 Mar;186(3):466-475. doi: 10.1111/bjd.20818. Epub 2021 Nov 24. Br J Dermatol. 2022. PMID: 34652810 Free PMC article.
-
Young patients with risk factors prevalent in the elderly - differences in comorbidity depending on severity of psoriasis: a nationwide cross-sectional study in Swedish health registers.Clin Epidemiol. 2018 Jun 19;10:705-715. doi: 10.2147/CLEP.S164918. eCollection 2018. Clin Epidemiol. 2018. PMID: 29950900 Free PMC article.
-
Cardiometabolic Disorders in Psoriatic Disease.Curr Rheumatol Rep. 2017 Aug 26;19(10):63. doi: 10.1007/s11926-017-0692-2. Curr Rheumatol Rep. 2017. PMID: 28844116 Review.
-
Treating adult patients of severe psoriasis with methotrexate leads to reduction in biomarkers of atherosclerosis: A prospective study.Med J Armed Forces India. 2024 Dec;80(Suppl 1):S174-S179. doi: 10.1016/j.mjafi.2023.03.004. Epub 2023 May 15. Med J Armed Forces India. 2024. PMID: 39734852
References
-
- Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137:280–284. - PubMed
-
- Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55:829–835. - PubMed
-
- Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735–1741. - PubMed
-
- Ludwig RJ, Herzog C, Rostock A, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol. 2007;156:271–276. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical